Fulminant type 1 diabetes mellitus developed about half a year after discontinuation of immune checkpoint inhibitor combination therapy with nivolumab and ipilimumab: A case report

Kazuma Yaura, Kanako Sakurai, Satsuki Niitsuma, Ryota Sato, Kazuhiro Takahashi, Zenei Arihara

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Fulminant type 1 diabetes mellitus developed about half a year after discontinuation of immune checkpoint inhibitor combination therapy with nivolumab and ipilimumab: A case report'. Together they form a unique fingerprint.

Medicine and Dentistry